WO2017067870A1 - Combination of trazodone and gabapentin for the treatment of pain - Google Patents

Combination of trazodone and gabapentin for the treatment of pain Download PDF

Info

Publication number
WO2017067870A1
WO2017067870A1 PCT/EP2016/074835 EP2016074835W WO2017067870A1 WO 2017067870 A1 WO2017067870 A1 WO 2017067870A1 EP 2016074835 W EP2016074835 W EP 2016074835W WO 2017067870 A1 WO2017067870 A1 WO 2017067870A1
Authority
WO
WIPO (PCT)
Prior art keywords
gabapentin
trazodone
salt
amount
pain
Prior art date
Application number
PCT/EP2016/074835
Other languages
French (fr)
Inventor
Beatrice Garrone
Lucia Durando
Fabrizio CALISTI
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/767,543 priority Critical patent/US10786498B2/en
Priority to LTEP16781816.0T priority patent/LT3364975T/en
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority to EP21158825.6A priority patent/EP3881845A3/en
Priority to EP16781816.0A priority patent/EP3364975B1/en
Priority to MDE20180825T priority patent/MD3364975T2/en
Priority to ES16781816T priority patent/ES2879392T3/en
Priority to AU2016341063A priority patent/AU2016341063B2/en
Priority to MX2018004532A priority patent/MX2018004532A/en
Priority to DK16781816.0T priority patent/DK3364975T3/en
Priority to KR1020187013499A priority patent/KR20180063314A/en
Priority to RS20210740A priority patent/RS61989B1/en
Priority to PL16781816T priority patent/PL3364975T3/en
Priority to EA201890911A priority patent/EA037838B1/en
Priority to UAA201804930A priority patent/UA122245C2/en
Priority to CN201680059627.1A priority patent/CN108174599B/en
Priority to IL258316A priority patent/IL258316B/en
Priority to BR112018007374-1A priority patent/BR112018007374B1/en
Priority to CA2999389A priority patent/CA2999389C/en
Priority to JP2018519360A priority patent/JP6924184B2/en
Priority to SI201631218T priority patent/SI3364975T1/en
Publication of WO2017067870A1 publication Critical patent/WO2017067870A1/en
Priority to US16/849,545 priority patent/US11752147B2/en
Priority to HRP20210832TT priority patent/HRP20210832T1/en
Priority to CY20211100546T priority patent/CY1124229T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of trazodone and gabapentin, said combination having a synergistic effect in the treatment of pain, in particular chronic pain.
  • Physiological pain is an important protective mechanism designed to warn of danger from potentially injurious stimuli from the external environment.
  • Intense acute pain and chronic pain may involve the same pathways driven by pathophysiological processes and as such cease to provide a protective mechanism and instead contribute to debilitating symptoms associated with a wide range of disease states. Pain is a feature of many trauma and disease states. When a substantial injury, via disease or trauma, to body tissue occurs the characteristics of nociceptor activation are altered.
  • pain can be divided into a number of different areas because of differing pathophysiology, these include nociceptive pain, inflammatory pain, chronic pain, neuropathic pain, and so on.
  • Nociceptive pain is induced by tissue injury or by intense stimuli with the potential to cause injury.
  • Neuropathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system.
  • the inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances, which result in swelling and pain.
  • Arthritic pain makes up the majority of the inflammatory pain population.
  • Rheumatoid disease is one of the commonest chronic inflammatory conditions in developed countries and rheumatoid arthritis is a common cause of disability.
  • Other types of inflammatory pain include but are not limited to inflammatory bowel diseases (IBD).
  • Chronic pain represents a series of pathologies from which, on average, about 10-20% of the adult population suffers. Chronic pain is generally associated with clinical conditions characterized by chronic and/or degenerative lesions.
  • Chronic pain differs from acute pain mainly by the duration.
  • Acute pain has a duration of a few days or weeks, correlated with recovery from the event that caused the pain (trauma, burns, intense efforts, surgical or dental interventions, and the like).
  • chronic pain persists for months and even years, causing muscular tension, limited mobility, fatigue, loss of appetite and apathy.
  • Typical examples of pathologies characterized by chronic pain are rheumatoid arthritis, osteoarthritis, fibromyalgia, neuropathies, etc. [Ashbum MA, Pope PS. Management of chronic pain. Lancet 1999; 353: 1865-69].
  • analgesic drugs currently used in the treatment of neuropathic pain include non-steroidal anti-inflammatory drugs (NSAID), antidepressants, opioid analgesics, and anticonvulsants [Woolf CJ, Mannion RJ, Neuropathic pain: aetiology, symptoms, mechanism, and management. Lancet 1999; 353: 1959-1964].
  • NSAID non-steroidal anti-inflammatory drugs
  • opioid analgesics opioid analgesics
  • anticonvulsants anticonvulsants
  • EP1663398B1 discloses a combination of an alpha-2-delta ligand such as gabapentin and pregabalin with a selective noradrenaline reuptake inhibitor such as (S,S)-reboxetine for the treatment of neuropathic pain.
  • WO 2013/002584 discloses a pain suppressive composition comprising two or more components selected from (a) 5-HT2 receptor antagonist, (b) a P2X receptor antagonist, and (c) any one of glycine receptor agonist, a glycine transporter antagonist, a gamma- aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GABA1 ) antagonist.
  • a pain suppressive composition comprising two or more components selected from (a) 5-HT2 receptor antagonist, (b) a P2X receptor antagonist, and (c) any one of glycine receptor agonist, a glycine transporter antagonist, a gamma- aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GABA1 ) antagonist.
  • Trazodone and a combination of trazodone and pregabalin have been studied in a 12- and 24-week treatment of fibromyalgia as disclosed in Morillas-Arques et al., "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC Musculoskeletal Disorders 2010, 1 1 :204 and Calandre et al., "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC Musculoskeletal Disorders 201 1 , 12:95.
  • the Applicant faced the problem to provide a pharmaceutical composition for the treatment of pain, in particular chronic pain, having an improved activity when compared to the compositions known in the art.
  • trazodone can be used in association with gabapentin.
  • the Applicant has now surprisingly found that the combination of trazodone with gabapentin has a synergistic effect in reducing pain in two experimental models in rats represented by (i) the inflammatory pain induced by injection of acetic acid, and (ii) the chronic pain induced by ligature of the sciatic nerve.
  • the experimental model of injection of acetic acid in rats represents an evaluation of the antinociceptive activity of the combination of the invention in a model of inflammatory pain.
  • Typical examples of human pathologies characterized by the dysfunctions described in the abovementioned experimental model and characterized by the presence of inflammatory pain are oedema, erythema, articular inflammation, osteoarthritis, rheumatoid arthritis and arthrosis.
  • the experimental model of ligature of the sciatic nerve in rats represents a neuropathy that reproduces a series of responses similar to those observed in man in numerous traumatic and pathological conditions associated with neuropathic pain.
  • the reason for this is that ligature of the sciatic nerve is capable of inducing a syndrome associated with the activation of specific circuits dedicated to controlling the perception of pain and characterized by the appearance of allodynia, hyperalgesia and spontaneous pain.
  • This model is well known to constitute a valid instrument for studying drugs to be used in the treatment of neuropathic pain in man, and in particular in controlling conditions such as allodynia and hyperalgesia.
  • Typical examples of human pathologies characterized by the dysfunctions described in the abovementioned experimental model and characterized by the presence of neuropathic pain are diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia, fibromyalgia and post-herpetic syndrome.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a synergistic combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of pain.
  • a second aspect of the present invention relates to a method for the treatment of pain, comprising administering to a subject in need thereof a synergistically effective amount of trazodone or a salt thereof and gabapentin or a salt or prodrug thereof.
  • Figure 1 visually shows the results of example 1 .
  • the ED 50 values of each drug (trazodone and gabapentin) are plotted on the X and Y axis. The line connecting both points is the theoretical line of additivity.
  • the experimental ED 50 value of the trazodone and gabapentin combination (ED 50 mix) is found significantly below the theoretical additive ED 50 value (ED 50 add).
  • Figure 2 visually shows the results of example 2.
  • the number of writhing counted within the 10 minutes after the administration of acetic acid are reported on the Y axis for each group of mice administered with the vehicle or ineffective amounts of trazodone and gabapentin alone or in combination as reported on the X axis.
  • Figure 3 visually shows the results of example 3.
  • the inhibition percentage expressed with reference to the result obtained with the vehicle, is reported on the Y axis for each group of mice administered with trazodone and gabapentin alone or in combination with a weight ratio as reported on the X axis.
  • Figure 3b only reported on the Y axis the inhibition percentage of the trazodone/gabapentin combination with a weight ratio as reported on the X axis.
  • Figure 4 visually shows the results of example 4.
  • the reversal percentage, expressed with reference to the result obtained with the vehicle, is reported on the Y axis for each group of rats administered with trazodone and gabapentin alone or in combination as reported on the X axis.
  • the expression "synergistic effect” means that the combination of trazodone with gabapentin inhibits the pain response in mice or rats at a concentration lower than the sum of the concentrations of trazodone and of gabapentin used alone for the same pain test to obtain the same inhibition.
  • a synergistic effect means that the combination of trazodone with gabapentin is effective in producing more than the additive effect of each component in the same pain test.
  • the pharmaceutical composition according to the present invention comprises trazodone or a salt thereof in an amount to provide an ineffective dosage if taken alone.
  • the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to or lower than 1 mg/kg, more preferably equal to or lower than 0.5 mg/kg, and even more preferably equal to or lower than 0.2 mg/kg.
  • the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to or higher than 0.01 mg/kg, more preferably equal to or higher than 0.05 mg/kg, and even more preferably equal to or higher than 0.1 mg/kg.
  • the pharmaceutical composition according to the present invention may contain trazodone or a salt thereof in any amount able to provide a dosage ranging from 0.01 mg/kg to 1 mg/kg, preferably ranging from 0.05 mg/kg to 0.5 mg/kg, more preferably from 0.1 mg/kg to 0.2 mg/kg, such as, for example, 0.02, 0.04, 0.07, 0.1 1 , 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.6, 0.7, 0.8, and 0.9 mg/kg, and the like.
  • the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to about 0.15 mg/kg.
  • the pharmaceutical composition according to the present invention may contain trazodone or a salt thereof in an amount equal to or lower than 70 mg, more preferably equal to or lower than 35 mg, and even more preferably equal to or lower than 15 mg.
  • the pharmaceutical composition according to the present invention comprises gabapentin or a salt or prodrug thereof in an amount to provide an ineffective dosage if taken alone.
  • the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or lower than 15 mg/kg, more preferably equal to or lower than 5 mg/kg, and even more preferably equal to or lower than 2 mg/kg.
  • the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or higher than 0.1 mg/kg, more preferably equal to or higher than 0.5 mg/kg, and even more preferably equal to or higher than 1 mg/kg.
  • the pharmaceutical composition according to the present invention may contain gabapentin or a salt or prodrug thereof in any amount able to provide a dosage ranging from 0.1 mg/kg to 15 mg/kg, preferably ranging from 0.5 mg/kg to 5 mg/kg, more preferably from 1 mg/kg to 2 mg/kg, such as, for example, 0.2, 0.4, 0.7, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 4.0, 6.0, 7.0, 8.0, and 9.0 mg/kg, and the like.
  • the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to about 1.5 mg/kg.
  • the pharmaceutical composition according to the present invention may contain gabapentin or a salt or prodrug thereof in an amount equal to or lower than 1000 mg, more preferably equal to or lower than 350 mg, and even more preferably equal to or lower than 150 mg.
  • the pharmaceutical composition according to the present invention contains an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio ranging from 1:40 to 10:1, preferably from 1 :20 to 1:1, and more preferably from 1 :15 to 1 :5.
  • any value within the above mentioned trazodone to gabapentin weight ratio can be used, such as, for example, 1:40, 1:39, 1:38, 1:37, 1:36, 1:35, 1:34, 1:33, 1:32, 1:31, 1:30, 1:29, 1:28, 1:27, 1:26, 1:25, 1:24, 1:23, 1:22, 1:21, 1:20, 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, and 9:1.
  • the pharmaceutical composition according to the present invention contains an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio of about 1 :10.
  • Prodrugs of gabapentin are included in the scope of the instant invention.
  • the chemically modified drug, or prodrug should have a different pharmacokinetic profile to the parent, enabling easier absorption across the mucosal epithelium, better salt formulation and/or solubility, improved systemic stability (for an increase in plasma half-life, for example).
  • the ester can be derived from the carboxylic acid moiety of the drug molecule by known means.
  • the amide may be derived from the carboxylic acid moiety or the amine moiety of the drug molecule by known means. Ester or amide derivatives may be cleaved by, for example, esterases or lipases.
  • the peptide may be coupled to the drug molecule via amide bond formation with the amine or carboxylic acid moiety of the drug molecule by known means.
  • Peptides may be recognized by specific or nonspecific proteinases.
  • the carbamate, N-acyloxyalkyl and N-acyloxyalkoxycarbonyl can be derived from the amine moiety of the drug molecule by known means. Such derivatives can be cleaved by esterases and/or decomposes spontaneously.
  • prodrugs are described, for example, in Stella V.J. et al, "Prodrug strategies to overcome poor water solubility", Advance Drug Delivery Reviews 59 (2007) 677-694, and in Simplicio A.L. et al., "Prodrugs for Amines", Molecules 2008, 13, 519-547.
  • gabapentin prodrug is the compound (1 - ⁇ [( ⁇ (1 RS)-1 -[isobutyryloxy]ethoxy ⁇ carbonyl)amino] methyl ⁇ cyclohexyl) acetic acid, commonly known as gabapentin enacarbil.
  • Salts of trazodone and gabapentin are included in the scope of the instant invention.
  • the salt can be formed with physiologically acceptable organic and inorganic compounds having an acid or a basic function.
  • suitable physiologically acceptable inorganic acids are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid.
  • Suitable physiologically acceptable organic acids are acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para- toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid.
  • Suitable physiologically acceptable inorganic bases are hydroxides, carbonates and hydrogen carbonates of ammonium, calcium, magnesium, sodium and potassium, for instance ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate.
  • Suitable physiologically acceptable organic bases are: arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, etha-nolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2- hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.
  • the pharmaceutical composition according to the present invention is for systemic use.
  • composition according to the present invention is formulated for oral or parenteral administration.
  • the pharmaceutical composition according to the present invention is prepared in suitable dosage forms.
  • suitable dosage forms are tablets, capsules, coated tablets, granules, and solutions and syrups for oral administration; creams, ointments transdermal patch and antiseptic plasters for topical administration; suppositories for rectal administration and sterile solutions for administration by injection, or aerosol or ophthalmic administration.
  • the dosage forms of the pharmaceutical composition of the present invention may be prepared according to techniques that are well known to pharmaceutical chemists, including mixing, granulation, tableting, dissolution, sterilization and the like.
  • these dosage forms are formulated so as to ensure a controlled release over time of a compound of the abovementioned general formula (I) or of a pharmaceutically acceptable salt thereof.
  • the required release time may be very short, normal or long.
  • the pharmaceutically acceptable excipient can be selected from the group comprising thickeners, glidants, binders, disintegrants, fillers, diluents, preservative, stabilizers, surfactants, buffers, fluidizers, lubricants, humectants, absorbents, salts for regulating osmotic pressure, emulsifiers, flavorings, colorants, sweeteners, and the like.
  • the pharmaceutical composition according to the present invention is effective for the treatment of pain.
  • the Applicant has found that the combination of trazodone with gabapentin has a synergistic effect in reducing pain in two experimental models in animals represented by (i) the inflammatory pain induced in mice by injection of acetic acid, and (ii) the chronic pain induced in rats by ligature of the sciatic nerve.
  • the pharmaceutical composition according to the present invention can be used to treat effectively and with high safety all kinds of chronic pain, either inflammatory or neuropathic in origin.
  • Preferred examples of chronic pain treated according to the present invention are the following:
  • test compounds were evaluated in the model of acetic acid- induced writhing in mice (Stock J.L. et al., J. Clin. Inv. 2001 , 107: 325 331 ).
  • Writhing test is a chemical method used to induce pain of peripheral origin by injection of acetic acid in mice. Analgesic activity is inferred from decrease in the frequency of writhing.
  • This test allowed evaluation of the antinociceptive activity of the compounds of the invention in a model of inflammatory pain.
  • Writhing is defined as a stretch, tension to one side, extension of hind legs, contraction of the abdomen so that the abdomen of mice touches the floor, turning the trunk (twist).
  • mice were orally treated with trazodone and gabapentin alone and in combination, or vehicle such as distilled water.
  • mice One hour after the treatment, an intraperitoneal injection of acetic acid (0.7% v/v in physiological saline, 16 ⁇ /g of body weight) was given to the mice to induce inflammatory pain and to check the effects of the test compound on the nociceptive response.
  • acetic acid 0.7% v/v in physiological saline, 16 ⁇ /g of body weight
  • the allodynia was induced by ligature under anaesthesia of the sciatic nerve of the left hind leg [Seltzer Z, Dubner R, Shir Y. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205-218; Bennet GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107].
  • the rats were treated with trazodone and gabapentin alone and in combination, or vehicle such as distilled water. After-treatment measurement was made at one hour following administration. The analgesic activity is evaluated as % reversal.
  • the ED50 values of trazodone, gabapentin and trazodone/gabapentin combination with a trazodone/gabapentin weight ratio equal to 1/10 has been determined using the writhing test in mice.
  • the theoretical additive ED50 of the trazodone/gabapentin combination should have been 14.5 mg/kg, so resulting in an interaction index of about 0.17, providing a strong indication of synergistic interaction.
  • mice The writhing test in mice was repeated by administering to four groups of mice ineffective increasing amounts of trazodone and gabapentin alone, or in combination with a trazodone/gabapentin weight ratio equal to 1/10, according to the following Table 2, and vehicle alone.
  • mice The writhing test in mice was repeated by administering to four groups of mice different ineffective amounts of trazodone and gabapentin alone, or in combination with different trazodone/gabapentin weight ratio, according to the following Table 3, and vehicle alone.
  • the test of ligature of the sciatic nerve in rats was employed to confirm the synergic effect of the combination of trazodone and gabapentin in the treatment of chronic neuropathic pain.
  • the test was done by administering to five groups of rats ineffective amounts of trazodone and gabapentin alone, or in combination with a trazodone/gabapentin weight ratio equal to 1 :10, and an effective amount of gabapentin according to the following Table 4 and vehicle alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.

Description

TITLE
COMBINATION OF TRAZODONE AND GABAPENTIN FOR THE TREATMENT OF PAIN
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition comprising a combination of trazodone and gabapentin, said combination having a synergistic effect in the treatment of pain, in particular chronic pain.
BACKGROUND OF THE INVENTION
Physiological pain is an important protective mechanism designed to warn of danger from potentially injurious stimuli from the external environment.
Intense acute pain and chronic pain may involve the same pathways driven by pathophysiological processes and as such cease to provide a protective mechanism and instead contribute to debilitating symptoms associated with a wide range of disease states. Pain is a feature of many trauma and disease states. When a substantial injury, via disease or trauma, to body tissue occurs the characteristics of nociceptor activation are altered.
There are a number of typical pain subtypes: 1 ) spontaneous pain which may be dull, burning, or stabbing; 2) pain responses to noxious stimuli are exaggerated (hyperalgesia); 3) pain is produced by normally innocuous stimuli (allodynia).
Therefore pain can be divided into a number of different areas because of differing pathophysiology, these include nociceptive pain, inflammatory pain, chronic pain, neuropathic pain, and so on.
Nociceptive pain is induced by tissue injury or by intense stimuli with the potential to cause injury.
Neuropathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system.
The inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances, which result in swelling and pain. Arthritic pain makes up the majority of the inflammatory pain population. Rheumatoid disease is one of the commonest chronic inflammatory conditions in developed countries and rheumatoid arthritis is a common cause of disability. Other types of inflammatory pain include but are not limited to inflammatory bowel diseases (IBD).
Chronic pain represents a series of pathologies from which, on average, about 10-20% of the adult population suffers. Chronic pain is generally associated with clinical conditions characterized by chronic and/or degenerative lesions.
Chronic pain differs from acute pain mainly by the duration. Acute pain has a duration of a few days or weeks, correlated with recovery from the event that caused the pain (trauma, burns, intense efforts, surgical or dental interventions, and the like). On the other hand, chronic pain persists for months and even years, causing muscular tension, limited mobility, fatigue, loss of appetite and apathy.
Typical examples of pathologies characterized by chronic pain are rheumatoid arthritis, osteoarthritis, fibromyalgia, neuropathies, etc. [Ashbum MA, Staats PS. Management of chronic pain. Lancet 1999; 353: 1865-69].
Chronic pain, and in particular neuropathic pain, is often debilitating and is a cause of loss of working capacity and of poor quality of life. Economic and social damage thus also follow.
The analgesic drugs currently used in the treatment of neuropathic pain include non-steroidal anti-inflammatory drugs (NSAID), antidepressants, opioid analgesics, and anticonvulsants [Woolf CJ, Mannion RJ, Neuropathic pain: aetiology, symptoms, mechanism, and management. Lancet 1999; 353: 1959-1964].
However, chronic pain, and in particular neuropathic pain, is notoriously difficult to treat with the drugs currently available. Consequently, the development of novel drugs has always been one of the main objectives of the pharmaceutical industry.
EP1663398B1 discloses a combination of an alpha-2-delta ligand such as gabapentin and pregabalin with a selective noradrenaline reuptake inhibitor such as (S,S)-reboxetine for the treatment of neuropathic pain.
WO 2013/002584 discloses a pain suppressive composition comprising two or more components selected from (a) 5-HT2 receptor antagonist, (b) a P2X receptor antagonist, and (c) any one of glycine receptor agonist, a glycine transporter antagonist, a gamma- aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GABA1 ) antagonist.
A review of the use of gabapentin in the treatment of neuropathic pain has been published by Kukkar A. et al, "Implications and mechanism of action of gabapentin in neuropathic pain", Arch. Pharm. Res. (2013) 36:237-251 . A superior effect was observed by the combination of gabapentin and venlafaxine in the rat spared nerve injury (SNI) model of neuropathic pain and by co-administration of gabapentin with donepezil and/or duloxetine against spinal nerve ligation-induced neuropathic pain and in spared nerve injury model. Trazodone and a combination of trazodone and pregabalin have been studied in a 12- and 24-week treatment of fibromyalgia as disclosed in Morillas-Arques et al., "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC Musculoskeletal Disorders 2010, 1 1 :204 and Calandre et al., "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC Musculoskeletal Disorders 201 1 , 12:95.
A combination of trazodone with fentanyl and paracetamol has been studied in a mouse model of visceral pain, showing a potent synergistic antinociceptive effect, as disclosed in Fernandez-Duehas et al., "Fentanyl-trazodone-paracetamol triple drug combination: Multimodal analgesia in a mouse model of visceral pain", Pharmacology, Biochemistry and Behavior 98 (201 1 ) 331-336.
Despite the numerous research efforts directed towards identifying a suitable analgesic compound, there is a significant number of patients whose pain condition still lacks a suitable treatment [Scholz J, Woolf CJ. Can we conquer pain? Nat Neusci. 2002; 5: 1062-76] and there is a continuous need to find novel treatments able to improve the patient conditions.
SUMMARY OF THE INVENTION
The Applicant faced the problem to provide a pharmaceutical composition for the treatment of pain, in particular chronic pain, having an improved activity when compared to the compositions known in the art.
The Applicant has found that trazodone can be used in association with gabapentin.
In particular, the Applicant has now surprisingly found that the combination of trazodone with gabapentin has a synergistic effect in reducing pain in two experimental models in rats represented by (i) the inflammatory pain induced by injection of acetic acid, and (ii) the chronic pain induced by ligature of the sciatic nerve.
As is known to those skilled in the art, the abovementioned experimental models may be considered as predictive of activity in man.
The experimental model of injection of acetic acid in rats represents an evaluation of the antinociceptive activity of the combination of the invention in a model of inflammatory pain.
Typical examples of human pathologies characterized by the dysfunctions described in the abovementioned experimental model and characterized by the presence of inflammatory pain are oedema, erythema, articular inflammation, osteoarthritis, rheumatoid arthritis and arthrosis.
The experimental model of ligature of the sciatic nerve in rats represents a neuropathy that reproduces a series of responses similar to those observed in man in numerous traumatic and pathological conditions associated with neuropathic pain. The reason for this is that ligature of the sciatic nerve is capable of inducing a syndrome associated with the activation of specific circuits dedicated to controlling the perception of pain and characterized by the appearance of allodynia, hyperalgesia and spontaneous pain. This model is well known to constitute a valid instrument for studying drugs to be used in the treatment of neuropathic pain in man, and in particular in controlling conditions such as allodynia and hyperalgesia.
Typical examples of human pathologies characterized by the dysfunctions described in the abovementioned experimental model and characterized by the presence of neuropathic pain are diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia, fibromyalgia and post-herpetic syndrome.
hus, in a first aspect, the present invention relates to a pharmaceutical composition comprising a synergistic combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of pain.
A second aspect of the present invention relates to a method for the treatment of pain, comprising administering to a subject in need thereof a synergistically effective amount of trazodone or a salt thereof and gabapentin or a salt or prodrug thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 visually shows the results of example 1 . The ED50 values of each drug (trazodone and gabapentin) are plotted on the X and Y axis. The line connecting both points is the theoretical line of additivity. The experimental ED50 value of the trazodone and gabapentin combination (ED50mix) is found significantly below the theoretical additive ED50 value (ED50add).
Figure 2 visually shows the results of example 2. The number of writhing counted within the 10 minutes after the administration of acetic acid are reported on the Y axis for each group of mice administered with the vehicle or ineffective amounts of trazodone and gabapentin alone or in combination as reported on the X axis.
Figure 3 visually shows the results of example 3. In Figure 3a, the inhibition percentage, expressed with reference to the result obtained with the vehicle, is reported on the Y axis for each group of mice administered with trazodone and gabapentin alone or in combination with a weight ratio as reported on the X axis. Figure 3b only reported on the Y axis the inhibition percentage of the trazodone/gabapentin combination with a weight ratio as reported on the X axis.
Figure 4 visually shows the results of example 4. The reversal percentage, expressed with reference to the result obtained with the vehicle, is reported on the Y axis for each group of rats administered with trazodone and gabapentin alone or in combination as reported on the X axis.
DETAILED DESCRIPTION OF THE INVENTION
In the present description, the expression "synergistic effect" means that the combination of trazodone with gabapentin inhibits the pain response in mice or rats at a concentration lower than the sum of the concentrations of trazodone and of gabapentin used alone for the same pain test to obtain the same inhibition. In other words, a synergistic effect means that the combination of trazodone with gabapentin is effective in producing more than the additive effect of each component in the same pain test.
The pharmaceutical composition according to the present invention comprises trazodone or a salt thereof in an amount to provide an ineffective dosage if taken alone.
Preferably, the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to or lower than 1 mg/kg, more preferably equal to or lower than 0.5 mg/kg, and even more preferably equal to or lower than 0.2 mg/kg. Preferably, the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to or higher than 0.01 mg/kg, more preferably equal to or higher than 0.05 mg/kg, and even more preferably equal to or higher than 0.1 mg/kg.
Accordingly, the pharmaceutical composition according to the present invention may contain trazodone or a salt thereof in any amount able to provide a dosage ranging from 0.01 mg/kg to 1 mg/kg, preferably ranging from 0.05 mg/kg to 0.5 mg/kg, more preferably from 0.1 mg/kg to 0.2 mg/kg, such as, for example, 0.02, 0.04, 0.07, 0.1 1 , 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.4, 0.6, 0.7, 0.8, and 0.9 mg/kg, and the like.
Advantageously, the pharmaceutical composition according to the present invention contains trazodone or a salt thereof in an amount to provide a dosage equal to about 0.15 mg/kg.
Accordingly, the pharmaceutical composition according to the present invention may contain trazodone or a salt thereof in an amount equal to or lower than 70 mg, more preferably equal to or lower than 35 mg, and even more preferably equal to or lower than 15 mg.
The pharmaceutical composition according to the present invention comprises gabapentin or a salt or prodrug thereof in an amount to provide an ineffective dosage if taken alone.
Preferably, the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or lower than 15 mg/kg, more preferably equal to or lower than 5 mg/kg, and even more preferably equal to or lower than 2 mg/kg.
Preferably, the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or higher than 0.1 mg/kg, more preferably equal to or higher than 0.5 mg/kg, and even more preferably equal to or higher than 1 mg/kg. Accordingly, the pharmaceutical composition according to the present invention may contain gabapentin or a salt or prodrug thereof in any amount able to provide a dosage ranging from 0.1 mg/kg to 15 mg/kg, preferably ranging from 0.5 mg/kg to 5 mg/kg, more preferably from 1 mg/kg to 2 mg/kg, such as, for example, 0.2, 0.4, 0.7, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 4.0, 6.0, 7.0, 8.0, and 9.0 mg/kg, and the like.
Advantageously, the pharmaceutical composition according to the present invention contains gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to about 1.5 mg/kg.
Accordingly, the pharmaceutical composition according to the present invention may contain gabapentin or a salt or prodrug thereof in an amount equal to or lower than 1000 mg, more preferably equal to or lower than 350 mg, and even more preferably equal to or lower than 150 mg.
Advantageously, the pharmaceutical composition according to the present invention contains an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio ranging from 1:40 to 10:1, preferably from 1 :20 to 1:1, and more preferably from 1 :15 to 1 :5.
Any value within the above mentioned trazodone to gabapentin weight ratio can be used, such as, for example, 1:40, 1:39, 1:38, 1:37, 1:36, 1:35, 1:34, 1:33, 1:32, 1:31, 1:30, 1:29, 1:28, 1:27, 1:26, 1:25, 1:24, 1:23, 1:22, 1:21, 1:20, 1:19, 1:18, 1:17, 1:16, 1:15, 1:14, 1:13, 1:12, 1:11, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, and 9:1.
Advantageously, the pharmaceutical composition according to the present invention contains an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio of about 1 :10.
Prodrugs of gabapentin are included in the scope of the instant invention. The chemically modified drug, or prodrug, should have a different pharmacokinetic profile to the parent, enabling easier absorption across the mucosal epithelium, better salt formulation and/or solubility, improved systemic stability (for an increase in plasma half-life, for example).
These chemical modifications may be (i) ester derivatives (ii) amide derivatives, (iii) carbamate derivatives, (iv) N-acyloxyalkyl derivatives, (v) N-acyloxyalkoxycarbonyl derivatives, (vi) peptides, and (vii) any combination thereof.
The ester can be derived from the carboxylic acid moiety of the drug molecule by known means. The amide may be derived from the carboxylic acid moiety or the amine moiety of the drug molecule by known means. Ester or amide derivatives may be cleaved by, for example, esterases or lipases.
The peptide may be coupled to the drug molecule via amide bond formation with the amine or carboxylic acid moiety of the drug molecule by known means. Peptides may be recognized by specific or nonspecific proteinases.
The carbamate, N-acyloxyalkyl and N-acyloxyalkoxycarbonyl can be derived from the amine moiety of the drug molecule by known means. Such derivatives can be cleaved by esterases and/or decomposes spontaneously.
Useful examples of suitable prodrugs are described, for example, in Stella V.J. et al, "Prodrug strategies to overcome poor water solubility", Advance Drug Delivery Reviews 59 (2007) 677-694, and in Simplicio A.L. et al., "Prodrugs for Amines", Molecules 2008, 13, 519-547.
An advantageously useful example of gabapentin prodrug is the compound (1 -{[({(1 RS)-1 -[isobutyryloxy]ethoxy}carbonyl)amino] methyl} cyclohexyl) acetic acid, commonly known as gabapentin enacarbil.
Salts of trazodone and gabapentin are included in the scope of the instant invention. The salt can be formed with physiologically acceptable organic and inorganic compounds having an acid or a basic function. Typical examples of suitable physiologically acceptable inorganic acids are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid.
Typical examples of suitable physiologically acceptable organic acids are acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para- toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid.
Typical examples of suitable physiologically acceptable inorganic bases are hydroxides, carbonates and hydrogen carbonates of ammonium, calcium, magnesium, sodium and potassium, for instance ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate and potassium hydrogen carbonate.
Typical examples of suitable physiologically acceptable organic bases are: arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2- dimethylaminoethanol, etha-nolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2- hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.
Preferably, the pharmaceutical composition according to the present invention is for systemic use.
More preferably the pharmaceutical composition according to the present invention is formulated for oral or parenteral administration.
Preferably, the pharmaceutical composition according to the present invention is prepared in suitable dosage forms.
Examples of suitable dosage forms are tablets, capsules, coated tablets, granules, and solutions and syrups for oral administration; creams, ointments transdermal patch and antiseptic plasters for topical administration; suppositories for rectal administration and sterile solutions for administration by injection, or aerosol or ophthalmic administration.
The dosage forms of the pharmaceutical composition of the present invention may be prepared according to techniques that are well known to pharmaceutical chemists, including mixing, granulation, tableting, dissolution, sterilization and the like.
Advantageously, these dosage forms are formulated so as to ensure a controlled release over time of a compound of the abovementioned general formula (I) or of a pharmaceutically acceptable salt thereof. Specifically, depending on the type of therapy, the required release time may be very short, normal or long.
The pharmaceutically acceptable excipient can be selected from the group comprising thickeners, glidants, binders, disintegrants, fillers, diluents, preservative, stabilizers, surfactants, buffers, fluidizers, lubricants, humectants, absorbents, salts for regulating osmotic pressure, emulsifiers, flavorings, colorants, sweeteners, and the like.
The pharmaceutical composition according to the present invention is effective for the treatment of pain.
The Applicant has found that the combination of trazodone with gabapentin has a synergistic effect in reducing pain in two experimental models in animals represented by (i) the inflammatory pain induced in mice by injection of acetic acid, and (ii) the chronic pain induced in rats by ligature of the sciatic nerve.
Accordingly, the pharmaceutical composition according to the present invention can be used to treat effectively and with high safety all kinds of chronic pain, either inflammatory or neuropathic in origin.
Preferred examples of chronic pain treated according to the present invention are the following:
inflammatory pain induced by oedema, erythema, articular inflammation, osteoarthritis, rheumatoid arthritis and arthrosis; and neuropathic pain induced by diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia, fibromyalgia and post-herpetic syndrome.
The examples that follow are intended for further illustration of the present invention, though without limiting it.
EXAMPLES
Description of the test methods
Writhing test in mice
The test compounds were evaluated in the model of acetic acid- induced writhing in mice (Stock J.L. et al., J. Clin. Inv. 2001 , 107: 325 331 ).
Writhing test is a chemical method used to induce pain of peripheral origin by injection of acetic acid in mice. Analgesic activity is inferred from decrease in the frequency of writhing.
This test allowed evaluation of the antinociceptive activity of the compounds of the invention in a model of inflammatory pain.
Writhing is defined as a stretch, tension to one side, extension of hind legs, contraction of the abdomen so that the abdomen of mice touches the floor, turning the trunk (twist).
Male CD-1 mice weighing 20-25 g were used for the test.
The mice were orally treated with trazodone and gabapentin alone and in combination, or vehicle such as distilled water.
One hour after the treatment, an intraperitoneal injection of acetic acid (0.7% v/v in physiological saline, 16 μΙ/g of body weight) was given to the mice to induce inflammatory pain and to check the effects of the test compound on the nociceptive response.
Five minutes after the administration of acetic acid and for the following 10 minutes the number of writhes was measured, which represents the parameter for evaluation of the nociceptive response. The analgesic activity is evaluated as % inhibition. Ligature of the sciatic nerve in rats
Male CD rats weighing 200-250 g on arrival were used.
The allodynia was induced by ligature under anaesthesia of the sciatic nerve of the left hind leg [Seltzer Z, Dubner R, Shir Y. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43: 205-218; Bennet GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107].
Two weeks after ligature of the sciatic nerve, rats who showed a reduction of at least 50% in the response threshold recorded before the intervention were selected. The pain threshold was measured with a von Frey machine, which makes it possible, by applying a gradual increase in pressure to the paw of the left hind leg of the rat, to record the nociceptive response, expressed in grams, corresponding to the moment at which the animal withdraws the leg.
Immediately after a pre-treatment measurement, the rats were treated with trazodone and gabapentin alone and in combination, or vehicle such as distilled water. After-treatment measurement was made at one hour following administration. The analgesic activity is evaluated as % reversal.
Results
Example 1
The ED50 values of trazodone, gabapentin and trazodone/gabapentin combination with a trazodone/gabapentin weight ratio equal to 1/10 has been determined using the writhing test in mice.
The results are summarized in the following Table 1 .
TABLE 1
Drug(s) ED50 (mg/kg)
Trazodone 1 .2 Gabapentin 27.8
Trazodone/Gabapentin 2.5
As illustrated in the Figure 1 , the theoretical additive ED50 of the trazodone/gabapentin combination should have been 14.5 mg/kg, so resulting in an interaction index of about 0.17, providing a strong indication of synergistic interaction.
Example 2
The writhing test in mice was repeated by administering to four groups of mice ineffective increasing amounts of trazodone and gabapentin alone, or in combination with a trazodone/gabapentin weight ratio equal to 1/10, according to the following Table 2, and vehicle alone.
The results of each test, expressed as reduction percentage of writhing number compared with the vehicle, are summarized in Table 2 and illustrated in Figures 2a, 2b and 2c.
TABLE 2
Drug(s) Amount (mg/kg) Writhing number reduction %
TEST 1 - FIGURE 2a
Trazodone 0.15 16.0
Gabapentin 1 .5 27.1
Trazodone/Gabapentin 0.15/1 .5 57.8
TEST 2 - FIGURE 2b
Trazodone 0.5 44.4
Gabapentin 5 38.1
Trazodone/Gabapentin 0.5/5 48.1 TEST 3 - FIGURE 2c
Trazodone 1 .5 57.1
Gabapentin 15 45.9
Trazodone/Gabapentin 1 .5/15 66.4
The results surprisingly demonstrated that the synergistic effect of the combination of trazodone gabapentin were evident only at the lowest dosage of trazodone and gabapentin employed in test 1 .
Example 3
The writhing test in mice was repeated by administering to four groups of mice different ineffective amounts of trazodone and gabapentin alone, or in combination with different trazodone/gabapentin weight ratio, according to the following Table 3, and vehicle alone.
The results of each test, expressed as reduction percentage of writhing number compared with the vehicle, are summarized in Table 3 and illustrated in Figure 3a and 3b.
TABLE 3
Drug(s) Amount (mg/kg) Writhing number reduction %
TEST 1 - RATIO 1 :20
Trazodone 0.075 2.1
Gabapentin 1 .5 29.2
Trazodone/Gabapentin 0.075/1 .5 47.6
TEST 2 - RATIO 1 :10
Trazodone 0.15 16.0
Gabapentin 1 .5 27.1
Trazodone/Gabapentin 0.15/1 .5 57.8 TEST 3 - RATIO 1 :5
Trazodone 0.15 16.3
Gabapentin 0.75 22.4
Trazodone/Gabapentin 0.15/0.75 44.4
TEST 4 - RATIO 1 :1
Trazodone 0.15 12.2
Gabapentin 0.15 28.3
Trazodone/Gabapentin 0.15/0.15 30.7
TEST 5 - RATIO 5:1
Trazodone 0.75 57.4
Gabapentin 0.15 30.2
Trazodone/Gabapentin 0.75/0.15 58.5
TEST 6 - RATIO 10:1
Trazodone 1 .5 59.7
Gabapentin 0.15 27.2
Trazodone/Gabapentin 1 .5/0.15 67.9
The results surprisingly demonstrated that the combination of trazodone and gabapentin having a trazodone/gabapentin weight ratio equal to 1 :10 showed the most enhanced synergistic analgesic activity.
Example 4
The test of ligature of the sciatic nerve in rats was employed to confirm the synergic effect of the combination of trazodone and gabapentin in the treatment of chronic neuropathic pain.
The test was done by administering to five groups of rats ineffective amounts of trazodone and gabapentin alone, or in combination with a trazodone/gabapentin weight ratio equal to 1 :10, and an effective amount of gabapentin according to the following Table 4 and vehicle alone.
The results of the test, expressed as reversal percentage compared with the vehicle, are summarized in Table 4 and illustrated in Figure 4.
TABLE 4
Figure imgf000018_0001
The results confirmed the synergic effect of the combination of trazodone and gabapentin in the treatment of chronic neuropathic pain, which resulted in an activity even higher than the activity obtained with a conventional effective dose of gabapentin alone.

Claims

1 . A pharmaceutical composition comprising a synergistic combination of trazodone or a salt thereof in an amount to provide a dosage equal to or lower than 1 mg/kg, and gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or lower than 15 mg/kg, and at least one pharmaceutically acceptable excipient, for use in the treatment of pain, wherein said pain is selected from the group consisting of chronic pain, inflammatory pain, and neuropathic pain.
2. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount to provide a dosage equal to or lower than 0.5 mg/kg and gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or lower than 5 mg/kg.
3. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount to provide a dosage equal to or lower than 0.2 mg/kg and gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to or lower than 2 mg/kg.
4. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount to provide a dosage equal to about 0.15 mg/kg and gabapentin or a salt or prodrug thereof in an amount to provide a dosage equal to about 1 .5 mg/kg.
5. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount equal to or lower than 70 mg and gabapentin or a salt or prodrug thereof in an amount equal to or lower than 1000 mg.
6. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount equal to or lower than 35 mg and gabapentin or a salt or prodrug thereof in an amount equal to or lower than 350 mg.
7. The pharmaceutical composition according to claim 1 , wherein said composition comprises trazodone or a salt thereof in an amount equal to or lower than 15 mg and gabapentin or a salt or prodrug thereof in an amount equal to or lower than 150 mg.
8. The pharmaceutical composition according to any one of the preceding claims 1 to 7, wherein said composition comprises an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio ranging from 1 :40 to 10:1 .
9. The pharmaceutical composition according to any one of the preceding claims 1 to 7, wherein said composition comprises an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio ranging from 1 :20 to 1 :1 .
10. The pharmaceutical composition according to any one of the preceding claims 1 to 7, wherein said composition comprises an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio ranging from 1 :15 to 1 :5.
1 1 . The pharmaceutical composition according to any one of the preceding claims 1 to 7, wherein said composition comprises an amount of trazodone or a salt thereof and an amount of gabapentin or a salt or prodrug thereof such as to provide a trazodone to gabapentin weight ratio of about 1 :10.
12. The pharmaceutical composition according to any one of the preceding claims 1 to 1 1 , for use in the treatment of chronic pain.
13. The pharmaceutical composition according to any one of the preceding claims 1 to 1 1 , for use in the treatment of inflammatory pain induced by oedema, erythema, articular inflammation, osteoarthritis, rheumatoid arthritis and arthrosis.
14. The pharmaceutical composition according to any one of the preceding claims 1 to 1 1 , for use in the treatment of neuropathic pain induced by diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia, fibromyalgia and post- herpetic syndrome.
PCT/EP2016/074835 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain WO2017067870A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
EA201890911A EA037838B1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
PL16781816T PL3364975T3 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
EP21158825.6A EP3881845A3 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
LTEP16781816.0T LT3364975T (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
MDE20180825T MD3364975T2 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
ES16781816T ES2879392T3 (en) 2015-10-22 2016-10-17 Trazodone and gabapentin combination for pain management
UAA201804930A UA122245C2 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
MX2018004532A MX2018004532A (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain.
DK16781816.0T DK3364975T3 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
KR1020187013499A KR20180063314A (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for pain treatment
RS20210740A RS61989B1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
US15/767,543 US10786498B2 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
EP16781816.0A EP3364975B1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
AU2016341063A AU2016341063B2 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
CN201680059627.1A CN108174599B (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
IL258316A IL258316B (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
BR112018007374-1A BR112018007374B1 (en) 2015-10-22 2016-10-17 PHARMACEUTICAL COMPOSITION
CA2999389A CA2999389C (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
JP2018519360A JP6924184B2 (en) 2015-10-22 2016-10-17 Pharmaceutical composition for the treatment of pain
SI201631218T SI3364975T1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
US16/849,545 US11752147B2 (en) 2015-10-22 2020-04-15 Pharmaceutical composition for the treatment of pain
HRP20210832TT HRP20210832T1 (en) 2015-10-22 2021-05-24 Combination of trazodone and gabapentin for the treatment of pain
CY20211100546T CY1124229T1 (en) 2015-10-22 2021-06-18 COMBINATION OF TRAZODONE AND GABAPENTIN FOR PAIN MANAGEMENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191024 2015-10-22
EP15191024.7 2015-10-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/767,543 A-371-Of-International US10786498B2 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain
US16/849,545 Division US11752147B2 (en) 2015-10-22 2020-04-15 Pharmaceutical composition for the treatment of pain

Publications (1)

Publication Number Publication Date
WO2017067870A1 true WO2017067870A1 (en) 2017-04-27

Family

ID=54345445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/074835 WO2017067870A1 (en) 2015-10-22 2016-10-17 Combination of trazodone and gabapentin for the treatment of pain

Country Status (27)

Country Link
US (2) US10786498B2 (en)
EP (2) EP3881845A3 (en)
JP (1) JP6924184B2 (en)
KR (1) KR20180063314A (en)
CN (1) CN108174599B (en)
AR (1) AR106415A1 (en)
AU (1) AU2016341063B2 (en)
BR (1) BR112018007374B1 (en)
CA (1) CA2999389C (en)
CY (1) CY1124229T1 (en)
DK (1) DK3364975T3 (en)
EA (2) EA037838B1 (en)
ES (1) ES2879392T3 (en)
GE (1) GEP20207145B (en)
HK (1) HK1252359A1 (en)
HR (1) HRP20210832T1 (en)
HU (1) HUE054653T2 (en)
IL (1) IL258316B (en)
LT (1) LT3364975T (en)
MD (1) MD3364975T2 (en)
MX (1) MX2018004532A (en)
PL (1) PL3364975T3 (en)
PT (1) PT3364975T (en)
RS (1) RS61989B1 (en)
SI (1) SI3364975T1 (en)
UA (1) UA122245C2 (en)
WO (1) WO2017067870A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900006602A1 (en) 2019-05-07 2020-11-07 Acraf Pharmaceutical composition for the treatment of neuropathic pain

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP1663398B1 (en) 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2013002584A2 (en) 2011-06-28 2013-01-03 주식회사 비보존 Combination of effective substances causing synergistic effects of multiple targeting and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006107534A (en) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) COMBINATION INCLUDING ALPHA-2-DELTA-LIGAND AND AND SSRI AND / OR SNRI FOR THE TREATMENT OF DEPRESSION AND ANXIETY DISORDER
WO2009012058A2 (en) * 2007-07-18 2009-01-22 Dow Global Technologies Inc. Water-glycol hydraulic fluid compositions
WO2010003046A2 (en) * 2008-07-02 2010-01-07 Teva Pharmaceutical Industries Ltd. Gabapentin enacarbil salts and processes for their preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663398B1 (en) 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US20080096872A1 (en) * 2004-12-22 2008-04-24 Friedman Robert S Composition for Treatment of Pain Specification
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2013002584A2 (en) 2011-06-28 2013-01-03 주식회사 비보존 Combination of effective substances causing synergistic effects of multiple targeting and use thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ASHBUM MA; STAATS PS: "Management of chronic pain", LANCET, vol. 353, 1999, pages 1865 - 69
BENNET GJ; XIE YK: "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man", PAIN, vol. 33, 1988, pages 87 - 107
CALANDRE ET AL.: "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC MUSCULOSKELETAL DISORDERS, vol. 12, 2011, pages 95, XP021099613, DOI: doi:10.1186/1471-2474-12-95
FERNANDEZ-DUENAS ET AL.: "Fentanyl-trazodone-paracetamol triple drug combination: Multimodal analgesia in a mouse model of visceral pain", PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 98, 2011, pages 331 - 336, XP028156094, DOI: doi:10.1016/j.pbb.2011.01.023
KUKKAR A. ET AL.: "Implications and mechanism of action of gabapentin in neuropathic pain", ARCH. PHARM. RES., vol. 36, 2013, pages 237 - 251, XP035312407, DOI: doi:10.1007/s12272-013-0057-y
MORILLAS-ARQUES ET AL.: "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC MUSCULOSKELETAL DISORDERS, vol. 11, 2010, pages 204, XP021076267, DOI: doi:10.1186/1471-2474-11-204
OKUDA K1 ET AL: "Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model", EUROPEAN JOURNAL OF ANAESTHESIOLOGY, PUBL. ON BEHALF OF THE EUROPEAN ACADEMY OF ANAESTHESIOLOGY AND THE EUROPEAN SOCIETY OF ANAESTHESIOLOGISTS, GB, vol. 20, no. 5, 1 May 2003 (2003-05-01), pages 409 - 415, XP009189324, ISSN: 0265-0215, DOI: 10.1017/S0265021503000632 *
SCHOLZ J; WOOLF CJ: "Can we conquer pain?", NAT NEUSCI., vol. 5, 2002, pages 1062 - 76
SELTZER Z; DUBNER R; SHIR Y.: "A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury", PAIN, vol. 43, 1990, pages 205 - 218, XP024377631, DOI: doi:10.1016/0304-3959(90)91074-S
SIMPLICIO A.L ET AL.: "Prodrugs for Amines", MOLECULES, vol. 13, 2008, pages 519 - 547, XP002710664, DOI: doi:10.3390/molecules13030519
STELLA V.J. ET AL.: "Prodrug strategies to overcome poor water solubility", ADVANCE DRUG DELIVERY REVIEWS, vol. 59, 2007, pages 677 - 694, XP022211987, DOI: doi:10.1016/j.addr.2007.05.013
STOCK J.L. ET AL., J. CLIN. INV., vol. 107, 2001, pages 325 - 331
WILSON RC1: "The use of low-dose trazodone in the treatment of painful diabetic neuropathy", JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, AMERICAN PODIATRIC MEDICAL ASSOCIATION, USA, vol. 89, no. 9, 1 September 1999 (1999-09-01), pages 468 - 471, XP009189323, ISSN: 8750-7315, DOI: 10.7547/87507315-89-9-468) *
WOOLF CJ; MANNION RJ: "Neuropathic pain: aetiology, symptoms, mechanism, and management", LANCET, vol. 353, 1999, pages 1959 - 1964, XP005062964, DOI: doi:10.1016/S0140-6736(99)01307-0

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900006602A1 (en) 2019-05-07 2020-11-07 Acraf Pharmaceutical composition for the treatment of neuropathic pain
WO2020225740A1 (en) * 2019-05-07 2020-11-12 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain

Also Published As

Publication number Publication date
EA202190626A2 (en) 2021-06-30
EP3364975B1 (en) 2021-04-07
IL258316B (en) 2022-08-01
AR106415A1 (en) 2018-01-10
US11752147B2 (en) 2023-09-12
CN108174599A (en) 2018-06-15
KR20180063314A (en) 2018-06-11
EA202190626A3 (en) 2021-09-30
HRP20210832T1 (en) 2021-08-06
RS61989B1 (en) 2021-07-30
EP3881845A3 (en) 2021-09-29
EP3364975A1 (en) 2018-08-29
CA2999389A1 (en) 2017-04-27
HUE054653T2 (en) 2021-09-28
PL3364975T3 (en) 2021-11-02
BR112018007374A2 (en) 2018-10-23
JP6924184B2 (en) 2021-08-25
ES2879392T3 (en) 2021-11-22
BR112018007374B1 (en) 2023-11-28
IL258316A (en) 2018-06-28
HK1252359A1 (en) 2019-05-24
GEP20207145B (en) 2020-08-25
MX2018004532A (en) 2018-09-12
AU2016341063B2 (en) 2022-04-14
US20180296553A1 (en) 2018-10-18
SI3364975T1 (en) 2021-08-31
UA122245C2 (en) 2020-10-12
CA2999389C (en) 2023-12-19
CN108174599B (en) 2021-09-03
EA037838B1 (en) 2021-05-26
US20200316060A1 (en) 2020-10-08
JP2018531259A (en) 2018-10-25
EP3881845A2 (en) 2021-09-22
DK3364975T3 (en) 2021-06-21
EA201890911A1 (en) 2018-09-28
AU2016341063A1 (en) 2018-04-26
MD3364975T2 (en) 2021-09-30
CY1124229T1 (en) 2022-05-27
LT3364975T (en) 2021-09-10
PT3364975T (en) 2021-05-27
US10786498B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
KR100557852B1 (en) Pharmaceutical composition for treating allodynia or other different types of chronic or phantom pain
EP0149544A2 (en) Pharmaceutical products providing enhanced analgesia
US11752147B2 (en) Pharmaceutical composition for the treatment of pain
AU2002257680A1 (en) Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
JP2018531259A6 (en) Pharmaceutical composition for the treatment of pain
WO1994016689A1 (en) Analgesic medicinal composition
EA045884B1 (en) COMBINATION OF TRAZODONE AND GABAPENTIN FOR THE TREATMENT OF PAIN
CN114288289A (en) Pharmaceutical composition with analgesic and/or antipruritic functions and application thereof
US20090062388A1 (en) Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain
Jadeja et al. Comparative study of single dose pre-emptive pregabalin vs. Placebo for post-operative pain relief in middle ear surgery
EP3965752B1 (en) Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain
EA046312B1 (en) PHARMACEUTICAL COMBINATION INCLUDING TRAZODONE FOR THE TREATMENT OF NEUROPATHIC PAIN
KR101779135B1 (en) Pharmaceutical composition comprising dexamethasone and ibuprofen for prevention and treating neuropathic pain
US20080081839A1 (en) Compounds useful for treating neurological disorders
BRPI0613281A2 (en) therapeutic combination containing an nmda receptor blocker and a narcotic analgesic substance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16781816

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2999389

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11201802335P

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 258316

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 15767543

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/004532

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2018519360

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018007374

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016341063

Country of ref document: AU

Date of ref document: 20161017

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201890911

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 14778

Country of ref document: GE

Ref document number: 20187013499

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201804930

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2016781816

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112018007374

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180412